Elevation Oncology Management
Management criteria checks 1/4
Elevation Oncology's CEO is Joe Ferra, appointed in Jan 2023, has a tenure of 1.5 years. total yearly compensation is $1.24M, comprised of 47.5% salary and 52.5% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $72.67K. The average tenure of the management team and the board of directors is 2 years and 2.6 years respectively.
Key information
Joe Ferra
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 47.5% |
| CEO tenure | 2yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling
May 03Elevation Oncology: Rising On News, But Not The Time To Buy
Jan 17Elevation Oncology GAAP EPS of -$0.86 misses by $0.07
Aug 04Elevation Oncology secured $50M loan facility with K2 HealthVentures
Jul 28We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely
May 10
We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate
Jan 25Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth
Sep 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$42m |
| Jun 30 2024 | n/a | n/a | -US$40m |
| Mar 31 2024 | n/a | n/a | -US$39m |
| Dec 31 2023 | US$1m | US$590k | -US$46m |
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$85m |
| Mar 31 2023 | n/a | n/a | -US$95m |
| Dec 31 2022 | US$775k | US$446k | -US$95m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$59m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$6m | US$238k | -US$32m |
Compensation vs Market: Joe's total compensation ($USD1.24M) is above average for companies of similar size in the US market ($USD642.68K).
Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.
CEO
Joe Ferra (49 yo)
2yrs
Tenure
US$1,243,856
Compensation
Mr. Joseph J. Ferra, Jr., also known as Joe, served as a Chief Financial Officer at Elevation Oncology, Inc. since June 2021 until July 12, 2023 and served as its Interim Chief Executive Officer until July...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2yrs | US$1.24m | 0.19% $ 72.7k | |
| Chief Scientific Officer | 2.8yrs | US$771.04k | 0% $ 0 | |
| Chief Medical Officer | 3.3yrs | US$836.06k | 0% $ 0 | |
| CFO & Secretary | 1.5yrs | no data | 0.0024% $ 937.9 | |
| Head of Tech Ops | 1.6yrs | no data | no data | |
| Senior Director of Corporate Communications & Investor Relations | no data | no data | no data | |
| Senior VP & General Counsel | 3yrs | no data | no data | |
| Senior Vice President of Business & Corporate Development | less than a year | no data | no data |
2.0yrs
Average Tenure
47.5yo
Average Age
Experienced Management: ELEV's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.5yrs | US$1.24m | 0.19% $ 72.7k | |
| Independent Director | 3.7yrs | US$86.48k | 0% $ 0 | |
| Independent Chairman of the Board | 5.7yrs | US$113.08k | 0% $ 0 | |
| Independent Director | 4.7yrs | US$84.48k | 0.080% $ 31.4k | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.6yrs
Average Tenure
61yo
Average Age
Experienced Board: ELEV's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 07:59 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Elevation Oncology, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Michael King | H.C. Wainwright & Co. |
| Silvan Tuerkcan | JMP Securities |